Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 and Osimertinib in EGFR-mutated NSCLC
NCT06391944Phase 2Active, not recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Nov 2021
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug in non-small cell lung cancer (NSCLC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Nov 2021; status: active, not recruiting.
02
Drugs
becotatug
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06391944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391944.